Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
A regenerative approach to the treatment of multiple sclerosis.
Precision medicine in chronic disease management: The MS BioScreen.
Spinal cord gray matter atrophy correlates with multiple sclerosis disability.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
MS Research Roundup: September 22, 2014
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
Episode 69 with Dr. Alessandra Solari on information and decision tools for newly diagnosed patients
ECTRIMS 2013 Day 4
Unusual association of Arnold-Chiari malformation and vitamin B12 deficiency.
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.
'Strikingly' Lower Familial Risk of MS Seen
Teriflunomide Gets High Marks in Yet Another Phase 3 Trial
Biogen Idec and Genentech Announce Restructuring of anti-CD20 Collaboration Agreement
5th Axon Degeneration Meeting
Safety study of BIIB033 in subjects with multiple sclerosis
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study.
CellCept Drug Details
Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis.
Episode 68 with Dr. Philip De Jager on the state of MS genetics
Nominations Open for Dystel Prize for MS Research
Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo.
Pages
« first
‹ previous
…
39
40
41
42
43
44
45
46
47
…
next ›
last »